Nerve Pain Archives - Amazing Health Advances

Chemotherapy Linked to Persistent Nerve Pain in 4 in 10 Cancer Patients

The AHA! Team — Mon, 10 Mar 2025 06:33:48 +0000

BMJ Group via News-Medical – The drugs used to treat cancer damage healthy cells and tissues, including the nervous system. Worldwide, cancer chemotherapy is linked to persistent severe peripheral nerve pain (neuropathy) for around 4 in every 10 patients treated with these drugs, suggests a pooled data analysis of the available evidence, published in the open access journal Regional Anesthesia & Pain Medicine. Notwithstanding wide regional variations, platinum based drugs, taxanes, and lung cancer seem to be associated with the highest rates of persistent painful neuropathy, lasting at least 3 months, the findings suggest, prompting the researchers to call for tailored approaches to pain relief. The drugs used to treat cancer damage healthy cells and tissues, including the nervous system. The effects can manifest in movement disturbances, such as loss of balance or coordination, and sensory disturbances, such as loss of sensation; numbness, tingling, “pins and needles”; or a burning sensation on the skin. Several factors influence the frequency and severity of chronic peripheral neuropathic pain, including type and dose of chemotherapy, pre-existing neuropathy, and the use of other drugs that can damage the nervous system, explain the researchers. The condition is thought to be caused by direct peripheral nerve cell damage which disrupts or rewires normal nerve signalling pathways, resulting in persistent pain, they add. Prompted by the growing number of cancer survivors and increasingly aggressive treatment of the disease, the researchers wanted to gauge the global prevalence of chronic painful peripheral neuropathy linked to chemotherapy. They scoured research databases for relevant studies published between 2000 and 2024, focusing on potentially influential sociodemographic, clinical, and methodological (study design, funding source, for example) factors. In all, they pooled the results of 77 eligible studies, involving 10,962 participants from 28 countries, all of whom had peripheral neuropathy that was associated with cancer drug treatment. In 4545 of these participants, this was painful and persistent, lasting for at least 3 months. The highest number of studies were carried out in the US (13) and Japan (10), and almost half were prospective observational studies. The cancers that featured most often were those of the bowel (25; 33%) and breast (17; 22%), while the largest proportion of studies focused on patients treated with either platinum based agents (13;17%), or taxanes (11; just over 14%), or both (6 ;8%), or the FOLFOX combination of folinic acid plus 5-fluorouracil plus oxalplatin (5; 6.5%). Pooled data analysis of the study results showed that the overall prevalence of persistent painful peripheral neuropathy was just over 41%. When stratified further, the analysis indicated that the highest prevalence was among patients treated with platinum based agents (40.5%) and taxanes (just over 38%). Prevalence was lowest among those treated with the FOLFOX combination (16.5%). Prevalence was also highest among those with primary lung cancer (just over 62%), possibly because of the complexities of treatment for this disease, suggest the researchers. Prevalence was lowest among those with primary ovarian cancer (31.5%) and lymphoma (36%). When stratified by continent, studies of patients in Asia reported the highest prevalence of persistent painful neuropathy (46.5%), while studies of patients in Europe reported the lowest (36%). Prevalence rates were similar in both men and women. The researchers emphasize that the design and methodology of the included studies differed substantially. And the overall certainty of evidence was considered to be low. Researchers emphasize that the design and methodology of the included studies differed substantially But they write: “Understanding the prevalence and predictors of chronic painful [chemotherapy induced peripheral neuropathy] is critical for promoting early diagnosis and developing personalized treatment strategies. “Our findings emphasize that chronic painful [chemotherapy induced peripheral neuropathy] represents a substantial global health challenge, affecting more than 40% of those diagnosed with [it].” And they conclude: “The wide variability in prevalence rates across different countries, continents, chemotherapy regimens, and primary cancer history underscores the need for tailored strategies to address this debilitating condition. “Future studies should focus on elucidating the mechanisms underlying these disparities and developing interventions that can reduce the burden of chronic painful [chemotherapy induced peripheral neuropathy] globally.” Source: BMJ Group Journal reference: D’Souza, R. S., et al. (2025). Global estimates of prevalence of chronic painful neuropathy among patients with chemotherapy-induced peripheral neuropathy: systematic review and meta-analysis of data from 28 countries, 2000–24. Regional Anesthesia & Pain Medicine. doi.org/10.1136/rapm-2024-106229 To read the original article click here.

The post Chemotherapy Linked to Persistent Nerve Pain in 4 in 10 Cancer Patients appeared first on Amazing Health Advances.

Scorpion Toxin That Targets ‘Wasabi Receptor’ May Help Solve Mystery of Chronic Pain

The AHA! Team — Sun, 01 Sep 2019 07:00:00 +0000

University of California, San Francisco via Science Daily – Researchers have discovered a scorpion toxin that targets the ‘wasabi receptor,’ a chemical-sensing protein found in nerve cells that’s responsible for the sinus-jolting sting of wasabi. Because the toxin triggers a pain response, scientists think it can be used as a tool for studying chronic pain and inflammation, and may eventually lead to the development of new kinds of non-opioid pain relievers. To read the original article click here.

The post Scorpion Toxin That Targets ‘Wasabi Receptor’ May Help Solve Mystery of Chronic Pain appeared first on Amazing Health Advances.

New Approaches to Heal Injured Nerves

The AHA! Team — Fri, 30 Aug 2019 07:00:00 +0000

Ruhr-University Bochum via EurekAlert – “Although we have so far only shown these effects in genetically modified mice and using gene therapy approaches, these findings open up various possibilities for the development of new drug approaches,” Injuries to nerve fibers in the brain, spinal cord, and optic nerves usually result in functional losses as the nerve fibers are unable to regenerate. A team from the Department of Cell Physiology at Ruhr-UniversitÃ¤t Bochum (RUB) led by Professor Dietmar Fischer has deciphered new mechanisms that enable the regeneration of such fibers. This could open up new treatment approaches for the brain, optic nerve, and spinal cord injuries. The researchers report on these results in the journal Nature Communications Biology on 23 August 2019. Intervention into Protein has Desirable and Undesirable Effects The brain, spinal cord, and optic nerves are referred to collectively as the central nervous system. The nerve fibers, called axons, are unable to grow back following injury, meaning that damage is permanent. “It is possible to partially restore the regenerative capacity of nerve cells in the central nervous system by eliminating the inhibiting protein PTEN,” explains Dietmar Fischer. “However, a knockout of this kind also triggers many different reactions in the cells at the same time, which often lead to cancer.” As a result, the direct inhibition of this protein is not suitable for therapeutic approaches in humans. What’s more, the originally postulated mechanism underlying the renewed regenerative capacity following PTEN knockout could not be confirmed in further studies, causing the researchers to seek alternative explanations. Only the Positive Effects Allowed While investigating this as-yet unclear mechanism, the Bochum-based researchers were able to show for the first time that PTEN knockout significantly inhibits an enzyme called glycogen synthase kinase 3, GSK3 for short. This enzyme, in turn, blocks another protein called collapsin response mediator protein 2, CRMP2. This means that the PTEN knockout prevents CRMP2 from being inhibited by GSK3. “If we directly prevent this second step, i.e., stop the inhibition of CRMP2, we can also achieve the regeneration-promoting effect in a more specific manner,” explains Dietmar Fischer. The activation of CRMP2 itself is not known to have any carcinogenic effect. Approaches for New Medications “Although we have so far only shown these effects in genetically modified mice and using gene therapy approaches, these findings open up various possibilities for the development of new drug approaches,” explains the neuropharmacologist Dietmar Fischer. Further studies in his department are investigating these options. To read the original article click here.

The post New Approaches to Heal Injured Nerves appeared first on Amazing Health Advances.